US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
News
Novartis links with NHS Cancer Vanguard sites
Swiss drug giant Novartis has announced the launch of two new joint working projects with national Cancer Vanguard sites, which aim to determine novel ways of boosting patient care pathways and access to services.
Charity forms Alzheimer’s disease taskforce
Alzheimer’s Research UK is calling on the NHS and the pharma industry to join its new taskforce to ensure people with dementia can access future treatments without unnecessary delay.
Skin conditions cost NHS £723m a year
New research shows that more than three million primary care hours are spent on skin conditions, at a cost to the NHS of £723 million each year.
NIHR launches new standards for public involvement in research
The National Institute for Health Research (NIHR) has launched a new set of national standards for public involvement in clinical research for use by organisations across the UK.
NICE rejects rare eye disease drug
Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.
Real world data back Sanofi’s Toujeo for type I diabetes
Sanofi has unveiled real-world data from the UK showing the efficacy of its long-acting basal insulin analogue Toujeo in treating patients in type I diabetes.
Napp secures distribution rights to Celltrion’s Herzuma
Napp Pharmaceuticals has secured itself exclusive UK distribution rights to Celltrion Healthcare’s Herceptin biosimilar Herzuma.
MPs call on government to help with Orkambi debate
MPs are calling on NHS England and Vertex to come to an agreement over the price of cystic fibrosis drug Orkambi.
Performance on A&E target slips further
NHS hospital performance against the four-hour A&E target stood at just 74.96 percent, well under the 95 percent target, for the week ending March 11th, show the most recent data from the Royal College of Emergency Medicine’s Winter Flow Project.
Coeliac UK launches new research fund and appeal
Coeliac UK has launched a new research fund and fundraising appeal that aims to raise £5 million to improve understanding and management of coeliac disease and gluten related autoimmune conditions.
Lundbeck snaps up Parkinson’s candidate via Prexton buy
Lundbeck has announced plans to buy Prexton Therapeutics in a deal valued at up to 905 million euros.
US nod for CSL Behring’s Hizentra
US regulators have cleared CSL Behring’s Hizentra for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder affecting the peripheral nerves that can cause permanent nerve damage.
PharmaTimes Clinical Researcher of the Year – The Americas: Book now!
Clinical researchers in the Americas have submitted their essays for this year’s competition and yesterday, the authors and finalists were revealed at a meeting of the executive steering group.
Number of prescriptions rises as net ingredient cost falls
The number of medicines prescribed on the NHS in England increased in 2017 but their net ingredient cost took a downturn, according to data released by NHS Digital.
